F. Travert
YOU?
Author Swipe
View article: Validation of the Body Scan®, a new device to detect small fiber neuropathy by assessment of the sudomotor function: agreement with the Sudoscan®
Validation of the Body Scan®, a new device to detect small fiber neuropathy by assessment of the sudomotor function: agreement with the Sudoscan® Open
Background Sudomotor dysfunction is one of the earliest manifestations of small fiber neuropathy (SFN), reflecting the alteration of sympathetic C fiber innervation of the sweat glands. Among other techniques, such innervation can be asses…
Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real‐life experience from a national reference network Open
Aim To describe baseline characteristics and follow‐up data in patients with lipodystrophy syndromes treated with metreleptin in a national reference network, in a real‐life setting. Patients and Methods Clinical and metabolic data from pa…
Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection Open
More than half of patients with COVID-19 pneumonia exhibit abnormal lung function 30 days after symptom onset, without clear relationship with pneumonia extent on chest CT. This pleads for systematic and long-term follow-up of patients wit…
View article: Islet-reactive CD8 <sup>+</sup> T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors
Islet-reactive CD8 <sup>+</sup> T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors Open
Islet-reactive CD8 + T cells are common in the periphery, but home to the pancreas preferentially in the context of type 1 diabetes.
View article: Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance
Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance Open
Exposure to HPV vaccines was not associated with an increased risk of ADs within the time period studied. Results were robust to case definitions and time windows of exposure. Continued active surveillance is needed to confirm this finding…
View article: Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: <scp>IMAGINE</scp> 3
Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: <span>IMAGINE</span> 3 Open
Aims To compare the efficacy and safety of basal insulin peglispro ( BIL ), which has a flat pharmacokinetic and pharmacodynamic profile and a long duration of action, with insulin glargine ( GL ) in patients with type 1 diabetes. Material…